b038a717-19be-40c4-a4df-992156b5e2a2
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 74.1026694045175
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.510
- MYC_TARGETS_V1+0.420
- E2F_TARGETS+0.340
- OXIDATIVE_PHOSPHORYLATION+0.330
- UV_RESPONSE_UP+0.330
- MTORC1_SIGNALING+0.320
- G2M_CHECKPOINT+0.310
- TGF_BETA_SIGNALING+0.310
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.290
- TNFA_SIGNALING_VIA_NFKB+0.260
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.260
- INTERFERON_GAMMA_RESPONSE-0.260
- BILE_ACID_METABOLISM-0.230
- PANCREAS_BETA_CELLS-0.200
- WNT_BETA_CATENIN_SIGNALING-0.200
- HEDGEHOG_SIGNALING-0.140
- IL6_JAK_STAT3_SIGNALING-0.140
- COMPLEMENT-0.130
- XENOBIOTIC_METABOLISM-0.110
- ALLOGRAFT_REJECTION-0.100
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-73-4670-01A-01R-1206-07 | — | cohortA4 | 0.787 |
| 2 | MDT-AP-0535 | Med | Medulloblastoma | 0.775 |
| 3 | MNG437 | — | — | 0.766 |
| 4 | TCGA-56-A5DR-01A-11R-A27Q-07 | — | cohortSQ1 | 0.766 |
| 5 | SRR4195653 | — | — | 0.758 |
| 6 | s0122203 | — | — | 0.752 |
| 7 | 6a8cad2e-350a-4c0b-9680-41d83ef1eb5d | — | — | 0.752 |
| 8 | TCGA-B6-A0RE-01A-11R-A056-07 | — | E | 0.745 |
| 9 | TCGA-92-8063-01A-11R-2247-07 | — | cohortSQ1 | 0.745 |
| 10 | MNG334 | — | — | 0.745 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 32 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.510 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.420 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.340 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.330 | Remibrutinib | — uncovered |
| UV_RESPONSE_UP | 0.330 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.320 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.310 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.310 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.290 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.260 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.250 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.190 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.180 | Inavolisib | — uncovered |
| APOPTOSIS | 0.170 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.160 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.140 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.130 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.120 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.120 | Idelalisib | — uncovered |
| PEROXISOME | 0.120 | Idelalisib | — uncovered |